Clinical Trials Arena40d agoneutral
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA marketmFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
66last 24h
973last 7d
109● bullish (7d)
123● bearish (7d)
212publishers
Barchart44d agoneutral
MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu VaccineModerna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!
InvestorsHub44d agoneutral
Moderna secures FDA approval for its first mRNA influenza vaccineModerna (NASDAQ:MRNA) announced on Thursday that the U. S.
The Wall Street Journal44d agoneutral
FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous ReviewThe Food and Drug Administration approved Moderna’s mRNA-based flu vaccine for adults ages 50 and older, clearing the first shot of its kind after a review process that nearly collapsed in February. The vaccine, called mFlusiva, uses the same mRNA technology as Moderna’s Covid-19 shots. It could reach pharmacies in time for the coming flu season, which typically starts in the fall.